Delivery Order SPE2DB20D9331-SPE2DB24FL0H6
Award Date
12/14/23
Potential Completion Date
1/8/24
Potential Value
$9.3K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order worth $7,737 under the Defense Logistics Agency's (DLA) SPE2DB24FL1C9 indefinite delivery contract. The contract is for the supply of the pharmaceutical product XOLAIR 75 MG/0.5 ML SYRINGE 0.5ML, with an ultimate completion date of June 7, 2024. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a wide range of...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $9,671.25 firm fixed-price delivery order is for the pharmaceutical product XOLAIR 150 MG/ML SYRINGEML, with a completion date of June 4, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue delivery...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $9,284.40 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, a pharmaceutical product, with an ultimate completion date of October 25, 2024. This award is part of a larger $499,999,999 indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, which allows the agency to...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of XOLAIR 150 MG/ML syringes. The $9,284.40 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA) under the SPE2DB program, which is a $499,999,999 indefinite delivery contract that allows the DLA to order a comprehensive range of pharmaceutical products to support the medical supply needs of the Department of Defense (DoD) healthcare facilities worldwide....
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is for the delivery of Xolair 150 mg/ml syringes. The $9,284.40 firm fixed-price delivery order was issued by the Defense Logistics Agency's (DLA) Medical Supply Chain division, which supports the recurring pharmaceutical needs of Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare facilities nationwide. DMS Pharmaceutical Group holds a significant...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense (DoD). The $4,642.20 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, a specialty pharmaceutical product, to fulfill the recurring medical supply needs of military health facilities. The award is not associated with any set-aside program. DMS Pharmaceutical Group holds a...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA) under the SPE2DB program. The $9,284.40 contract is for the supply of XOLAIR 150 MG/ML SYRINGE/ML, a specialty pharmaceutical product. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a wide range of medications and medical supplies to the Department of Defense (DoD) and...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order valued at $9,284.40. The contract was awarded by the Defense Logistics Agency (DLA) and has no set-aside designation. It is part of the DLA's larger SPE2DB Indefinite Delivery Contract (IDC) valued at up to $499,999,999, which allows the agency to issue delivery orders for a comprehensive range of pharmaceutical products to support the medical supply needs of...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a Delivery Order under the Defense Logistics Agency's (DLA) SPE2DB indefinite delivery contract (IDC). The IDC, valued up to $499,999,999, allows the DLA to issue firm fixed-price delivery orders for a wide range of pharmaceutical products to support the recurring medical supply needs of military health facilities worldwide. The specific award, valued at $9,284.40, is for the supply of XOLAIR 150 MG/ML...
This federal contract award is a delivery order valued at $9,284.40 issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The award is for the supply of XOLAIR 150 MG/ML SYRINGEML, a specialized pharmaceutical product. The contract is a firm fixed-price delivery order with a period of performance through March 13, 2025. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract (IDC) with the DLA...